Benzinga | May 27, 2021 04:33PM EDT

Cyclerion Therapeutics Highlights Publication Of CY6463 Preclinical Data In Frontiers In Pharmacology

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) today announced the publication of preclinical data of CY6463 in Frontiers in Pharmacology. Cyclerion is developing CY6463, an oral, first-in-class, central nervous system (CNS)-penetrant sGC stimulator, for neurological diseases associated with cognitive impairment, including Alzheimer's disease with vascular pathology (ADv), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS), as well as Cognitive Impairment Associated with Schizophrenia (CIAS).